77% of narcolepsy type 1 patients still experience cataplexy attacks despite treatment, per Axsome Therapeutics survey.

Axsome Therapeutics reveals results from a CRESCENDO narcolepsy patient survey, showing 77% of narcolepsy type 1 patients still experience cataplexy attacks despite treatment. 64% continue to experience excessive daytime sleepiness, while 74% show cognitive impairment. Depression and anxiety affect 45% and 57% of patients, respectively. The survey highlights unmet needs in the treatment of narcolepsy type 1.